#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Congenital hypotransferrinaemia Glioma Systemic lupus erythematosus Factor VIII deficiency Dementia Myelodysplastic syndrome with excess blasts Li-Fraumeni syndrome Cerebellar ataxia Osteosarcoma metastatic Fatty acid oxidation disorder Alpha-1 antitrypsin deficiency Myocarditis Myeloproliferative neoplasm Primary hyperoxaluria Pleural mesothelioma More trials…

    Learn about Rare Diseases

    Niemann-Pick disease – Trials in Disease Marginal zone lymphoma – Trials in Disease Pleural mesothelioma malignant – Basic Information Erdheim-Chester disease – Trials in Disease Osteosarcoma recurrent – Trials in Disease Testicular leiomyosarcoma – Life with Disease Kearns-Sayre syndrome – Trials in Disease Burkitt’s lymphoma – Life with Disease Undifferentiated sarcoma Urea cycle disorder More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    D-Camphor Ataluren O15-Water TUB-030 Petrelintide Triamcinolone A52 Nimotuzumab Pf-07220060 Monohydrate Cemdisiran TORASEMIDE Fluvastatin Sodium Orismilast D-Biotin Ketoprofen Atorvastatin Calcium Oregovomab DCC-3084 Brigatinib Cls12311 More therapies…

    Learn about Your Condition

    Fatty acid oxidation disorder Sleep disorder Myeloid leukaemia Hidradenitis Acarodermatitis Hepatitis B Metastatic gastric cancer Adrenal insufficiency Fibrosarcoma Candida infection Testicular germ cell tumour Brain injury Atrial flutter Arrhythmia Hypercholesterolaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre de Radiothérapie Guillaume le Conquérant

Centre de Radiothérapie Guillaume le Conquérant

61 Rue Denfert Rochereau, Le Havre, 76600, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of ivonescimab alone or with ligufalimab versus pembrolizumab for patients with recurrent or metastatic head and neck squamous cell cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • LIGUFALIMAB
    • Ivonescimab
    • Pembrolizumab
    Belgium France Spain

  • Study of Dostarlimab Combined with Short Course Radiotherapy for Locally Advanced Rectal Cancer Patients with Microsatellite Instability

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Microsatellite instability cancer
    • Rectal cancer
    Investigated Drugs:
    • Dostarlimab
    France

  • Study of avelumab and cetuximab combination treatment after TPEx chemotherapy for patients with recurrent or metastatic head and neck cancer receiving first-line therapy

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Avelumab
    • Carboplatin
    • Cetuximab
    France

  • Evaluation of Bevacizumab in Patients with Brain Radionecrosis After Radiation Treatment for Brain Metastases

    Recruiting

    3 1 1
    Investigated Diseases:
    • Metastases to central nervous system
    Investigated Drugs:
    • Bevacizumab
    • Prednisolone
    • Sodium Chloride
    France

  • Study on Darolutamide and Radiation Therapy for Patients with Castration-Resistant Prostate Cancer and Oligometastases

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone-refractory prostate cancer
    Investigated Drugs:
    • Goserelin
    • Triptorelin
    • Darolutamide
    Belgium France Ireland Spain

  • Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • PUCOTENLIMAB
    France

  • Study on the Safety and Tolerance of Durvalumab and Radiotherapy for Patients with Untreated Head and Neck Squamous Cell Carcinoma

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Durvalumab
    France

  • Study on Adding Nivolumab to Cisplatin and Radiotherapy for High-Risk Patients with Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • Cisplatin
    • Nivolumab
    Belgium France Greece Poland Spain

  • Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Avelumab
    • Cetuximab
    • Cisplatin
    France
1 2
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!